Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance
Menée sur 18 patients atteints d'un cancer du poumon non à petites cellules avec mutations ALK, cette étude identifie divers mécanismes de résistance au crizotinib
Mutated anaplastic lymphoma kinase (ALK) drives the development of multiple tumor types, and ALK tyrosine kinase inhibitors such as crizotinib have been validated as targeted therapeutics. Unfortunately, as with other oncogene-driven tumors, therapeutic resistance invariably develops. In Science Translational Medicine, two recent studies provide new insight into mechanisms of resistance to ALK tyrosine kinase inhibitors and possible strategies to overcome this resistance.
Science Translational Medicine , commentaire, 2012